ArticleAACE endocrinology and diabetes
A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Maturity-onset diabetes of the young (MODY) is a form of autosomal dominant monogenic diabetes. Sulfonylureas are the mainstay of therapy for hepatocyte nuclear factor 4A (HNF4A) MODY. Here, we present a patient with HNF4A MODY successfully treated with oral semaglutide. Case Description: A 58-year-old woman with diabetes presented for evaluation. Body mass index was 23.3 kg/m Discussion: To our knowledge, this is the first case of HNF4A MODY to be treated with oral semaglutide alone. Oral glucagon-like peptide receptor-1 receptor agonists may be used to treat HNF4A MODY as an independent or adjunctive therapy to sulfonylureas. Both medications work via different mechanisms to bypass the malfunctioning pathway caused by the HNF4A MODY variant. Conclusion: Glucagon-like peptide 1 receptor agonists, including oral semaglutide, may be safe and efficacious treatments for patients with HNF4A MODY.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.